Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.54 |
| ▸ | PPARA | Q07869 | 12/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779922 | 1.00 | PPARG (0.54) | PPARGPPARACYP2C9CYP2C19PPARD | |
| SCHEMBL4575361 | 0.87 | FBP1 (0.44) | PPARGPPARANR1H3FBP1BCHE | |
| SCHEMBL4575360 | 0.87 | FBP1 (0.44) | PPARGPPARANR1H3FBP1BCHE | |
| SCHEMBL4843078 | 0.76 | L3MBTL1 (0.42) | NR1H3 | |
| SCHEMBL4843067 | 0.76 | L3MBTL1 (0.42) | NR1H3 | |
| SCHEMBL4841559 | 0.75 | CYSLTR2 (0.44) | NR1H3 | |
| SCHEMBL4841552 | 0.75 | CYSLTR2 (0.44) | NR1H3 | |
| SCHEMBL2174559 | 0.75 | PPARA (0.51) | PPARGPPARACYP2C9CYP2C19PPARD | |
| SCHEMBL29451792 | 0.75 | HSD17B10 (0.41) | NR1H3BCHE | |
| SCHEMBL6752627 | 0.72 | CYP1A2 (0.44) | CYP2C9NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176445-A1 | Propionic acid derivatives | BAYER PHARMACEUTICALS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6750236-B2 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1328508-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| WO-2002028821-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885CYP2C9 1909/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP2C9 2874/4885 |
| US-20040176445-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP2C9 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.